Subscribe for $2

Subscribe for 2 $

Financial Data API

Terminal Financial Data API

Daiichi Sankyo Co Aktie News & Pressemeldungen

Daiichi Sankyo Co Eulerpool News

12/24/2024, 1:19:12 PM

Rückschlag für innovatives Krebsmedikament: AstraZeneca und Daiichi Sankyo ziehen Antrag zurück

12/24/2024, 11:16:16 AM

AstraZeneca zieht Antrag auf Arzneimittelzulassung in Europa zurück

11/1/2024, 8:19:46 AM

Merck zeigt starke Performance im dritten Quartal 2024: Wachstum durch innovative Entwicklungen und globale Expansionsstrategien

10/9/2024, 6:22:47 PM

Myriad Genetics setzt auf strategische Allianzen zur Erforschung von MRD-Tests im Brustkrebsmanagement

8/1/2024, 4:32:36 PM

Milliarden-Investition von Sanofi stärkt Frankfurter Pharmastandort

1

2

1

2

Daiichi Sankyo Co Stock News

Daiichi Sankyo Co is being monitored by journalists and investors worldwide. We gather the latest Daiichi Sankyo Co news here.

February 4 ·
SeekingAlpha
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
January 31 ·
SeekingAlpha
Daiichi Sankyo Company, Limited 2024 Q3 - Results - Earnings Call Presentation
January 31 ·
SeekingAlpha
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript
January 10 ·
SeekingAlpha
High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower
December 26 ·
Yahoo
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
December 24 ·
Yahoo
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn
December 11 ·
Yahoo
Daiichi Sankyo doses first subject in Phase III AML therapy trial
December 10 ·
Yahoo
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
December 10 ·
Yahoo
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML
December 9 ·
Yahoo
Daiichi Sankyo secures breakthrough designation for NSCLC treatment

1

2

1

2

Daiichi Sankyo Co Stock Press Releases

Daiichi Sankyo Co regularly publishes news on the company's website that are relevant for investors.

Access the world's leading financial data and tools

Subscribe for $2